Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer
Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer
复制标题
DOI：
10.1016/j.anndiagpath.2019.01.002
复制
发表时间：
2019-04-01
影响因子：
2
通讯作者：
Matar, Ihab
中科院分区：
文献类型：
--
作者：
Abdelrahman, Aziza E.;Rashed, Hayam E.;Matar, Ihab
非肌层浸润性膀胱癌（NMIBC）是一种异质性疾病，其进展为肌层浸润性膀胱癌（MIBC）的风险不可预测。选择可能受益于早期根治性干预的患者是一项挑战。为了确定有用的进展预后标志物，我们分析了60例接受TURBT和辅助膀胱内卡介苗（BCG）的NMIBC中脂肪酸合成酶（FXR）、Her 2/neu和E2 F1的免疫组化表达。分析它们对肿瘤复发、进展、无复发生存期（RFS）和无进展生存期（PFS）的预测作用。在56.7%（34/60）的NMIBC病例中观察到高表达，并且FcB表达与肿瘤大小、分级和肿瘤分期显著相关（分别为p = 0.003，p < 0.001，p < 0.0001）。Her 2/neu阳性率为18.3%（11/60），其表达与肿瘤大小、组织学分级和肿瘤分期显著相关（分别为p = 0.001、p = 0.002和p = 0.011）。在40%的病例中检测到E2 F1的高表达，并且其与肿瘤大小、组织学分级和肿瘤分期相关（每种均为p < 0.001）。随访期分析显示，高FXR、阳性Her 2/neu和高E2 F1表达的NMIBC与肿瘤进展、较短的RFS和较差的PFS表现出有力的相关性。结论：高FEV 1、Her 2/neu和E2 F1被认为是NMIBC中肿瘤复发和进展的不良预后因素，应仔细随访这些患者。因此，我们建议在为NMIBC患者选择适当的管理策略时，应考虑和评估FEV 1、Her 2/neu和E2 F1。
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease which has an unpredictable risk of progression to muscle-invasive bladder cancer (MIBC). The selection of patients who may benefit from early radical intervention is a challenge. To define the useful prognostic markers for progression, we analyzed the immunohistochemical expression of fatty acid synthase (FASN), Her2/neu, and E2F1 in 60 cases of NMIBC who underwent TURBT and adjuvant intravesical bacillus-Calmette-Guerin (BCG). Their predicting role for tumor recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS) was analyzed. High FASN expression was observed in 56.7% (34/60) of NMIBC cases, and FASN expression was significantly associated with the tumor size, grade, and tumor stage (p = 0.003, p < 0.001, p < 0.0001 respectively). Positive Her2/neu was noted in 18.3% (11/60) of the cases, and its expression was significantly associated with the tumor size, histologic grade, and tumor stage (p = 0.001, p = 0.002, p = 0.011 respectively). High E2F1 expression was detected in 40% of the cases, and it was associated with tumor size, histologic grade, and tumor stage (p < 0.001 for each). Analysis of follow-up period revealed that NMIBC with high FASN, positive Her2/neu, and high E2F1 expression exhibited a potent relation with tumor progression, shorter RFS, and poor PFS. Conclusions: High FASN, Her2/neu, and E2F1 are considered as adverse prognostic factors of tumor recurrence and progression in NMIBC and these patients should be followed carefully. Therefore, we suggest that FASN, Her2/neu, and E2F1 should be considered and evaluated during the selection of the appropriate management strategy for NMIBC patients.